Comparison of clinical staging algorithms and 111Indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients

Cancer

Volumn 85, Issue 7, 1999, Pages 1586-1592

  Polascik, Thomas J ^a,e   Manyak, Michael J ^b   Haseman, Michael K ^c   Gurganus, Robin T ^a   Rogers, Barbara ^d   Maguire, Robert T ^d   Partin, Alan W ^a,f  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c Sutter General Hospital   (United States)

^d Cytogen Corporation   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

111Indium capromab pendetide; Immunoscintigraphy; Lymph node involvement; Prostate carcinoma; Staging

Indexed keywords

CAPROMAB PENDETIDE IN 111; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; HUMAN; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ALGORITHMS; ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; ROC CURVE;

EID: 0033120306     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990401)85:7<1586::AID-CNCR21>3.0.CO;2-F     Document Type: Article

References (23)

1. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomical radical prostatectomy: the Johns Hopkins experience after 10 years, Urol Clin North Am 1993;20:713-25.
2. Pound CR, Partin AW, Epstein JI, Walsh PC. PSA following anatomical radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 1997;24: 395-406.
3. Sobin LH, Wittekind C. TNM classification of malignant tumours. 5th edition. New York: John Wiley and Sons Inc., 1997.
4. Partin AW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, Kattan MW, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445-51.
5. Tempany CM, Zhou X, Zerhouni EA, Rifkin MD, Quint LE, Piccoli CW, et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 1994;193:47-54.
6. Wolf JS, Cher M, Dall'era M, Presti JC Jr., Hricak H, Carroll PR. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995; 153:993-9.
7. 111In-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 1998;159:2041-7.
8. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998;83:739-47.
9. Burgers JK, Hinkle GH, Haseman MK. Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol 1995;13:103-12.
10. Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with 111-indium-labeled monoclonal antibody CYT-356. J Urol 1994;152:1952-5.
11. Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Cancer 1993;72(Suppl):3453-62.
12. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994;151:1315-20.
13. Roach M III, Marquez C, Hae-Sook Y, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate-specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;28:33-7.
14. Sands ME, Zagars GK, Pollack A, von Eschenbach AC. Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer. Urology 1994;44:215-20.
15. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-5.
16. Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr., Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 1987;138:92-8.
17. Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, et al. Immunoscintigraphy of prostatic cancer: preliminary results with indium-111-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991;18:229-41.
18. Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-29.
19. Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, et al. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 1997;33:281-5.
20. Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, et al. Preliminary imaging results using In-111 labeled CYT-356 (ProstaScint®) in the detection of recurrent prostate cancer. Clin Nucl Med 1996;21:759-67.
21. Hanks GE, Myers CE, Scardino PT. Cancer of the prostate. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia: J.B. Lippincott Co., 1993;1073-113.
22. Saitoh H, Yoshida KI, Uchijima Y, Kobayashi N, Suwata J, Kamata S. Two different lymph node metastatic patterns of a prostatic cancer. Cancer 1990;65:1843-6.
23. 111In-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology (in press).